Colorectal Cancer

Rene Adam, MD, PhD, discusses future research aimed at reducing the risk of recurrence in patients with unresectable colorectal liver metastases

Chiara Cremolini, MD, PhD, discusses the implications of the TRANSMET trial in patients with unresectable colorectal liver metastases.

Tanios Bekaii-Saab, MD, FACP, discusses final results from the MOUNTAINEER trial in HER2+ metastatic colorectal cancer.

The Guardant Reveal test was accurate in predicting disease recurrence in stage II or higher colorectal cancer.

ABBV-400 displayed efficacy and tolerability in microsatellite stable/mismatch repair–proficient advanced colorectal cancer.

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

The Shield blood test has been approved by the FDA for CRC screening in adults aged 45 years and older who are at average risk for the disease.

Richard Kim, MD, discusses the standard treatment approaches and unmet needs for patients with resectable colorectal cancer.

The FDA completed an end-of-phase 2 meeting for botensilimab plus balstilimab in relapsed/refractory microsatellite stable colorectal cancer.

Tanios S. Bekaii-Saab, MD, highlights data from the phase 1/2 ARC-9 study which showed promising overall survival data in patients with colorectal cancer.

Chun Chao, PhD, MS, discusses the association between the use of broad-spectrum antibiotics and the risk of developing early-onset colorectal cancer.

A phase 3, randomized, double-blind, placebo-controlled study to determine if prior TAS-102 and/or regorafenib treatment status and sequence affect the efficacy and safety of fruquintinib in patients with mCRC. This study used data from both FRESCO (NCT02314819) and FRESCO-2 (NCT04322539).

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Richard Kim, MD, on efficacy data for NT-I7 plus pembrolizumab in pretreated microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma.

Salman R. Punekar, MD discusses the rationale for evaluating safety and preliminary anti-tumor activity of NT-112 in solid tumors with the KRAS G12D mutation.

Pembrolizumab plus bevacizumab and CAPOX produced responses in pMMR/MSS metastatic colorectal cancer with high immune infiltrate.

Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Aparna Parikh, MD, discusses key findings from the HERKULES-3 study and what the future of the BRAF-mutated mCRC treatment paradigm may look like.

Chun Chao, MS, PhD, discusses the impact of broad-spectrum antibiotic use on the risk of developing early-onset colorectal adenocarcinoma.

TAS-102 followed by regorafenib is an optimal sequence vs regorafenib followed by TAS-102 in select patients with metastatic colorectal cancer.

Christos Kyriakopoulos, MD discusses two correlative studies conducted within the CHAARTED2 trial.

Chiara Cremolini, MD, discusses the role of ctDNA in assessing minimal residual disease in patients with CRC.

Celecoxib plus adjuvant chemotherapy led to extended DFS and OS vs placebo plus adjuvant chemotherapy in PIK3CA-mutated stage III colon cancer.

First-line cetuximab beta injection has received NMPA marketing approval in RAS/BRAF wild-type metastatic colorectal cancer.